AI Article Synopsis

  • - A 55-year-old man with nasopharyngeal carcinoma underwent successful initial treatment but later died due to severe complications during adjuvant chemotherapy (TPF therapy).
  • - He developed febrile neutropenia, shock, and ultimately succumbed to multiple infections, including MRSA pneumonia, after 43 days of treatment.
  • - The autopsy indicated acute respiratory distress syndrome as the primary cause of death, highlighting the need for thorough patient education and consent regarding the risks of TPF therapy, which has a mortality rate of 2-4%.

Article Abstract

Chemotherapy-related death can occur, but is rarely experienced in the case of head and neck cancer. In this report, we present the case of a 55-year-old male who died of a severe febrile neutropenia during adjuvant chemotherapy. He was initially diagnosed as having nasopharyngeal carcinoma (cT2N0M0), and concurrent chemoradiotherapy was used as a primary treatment. He did not show any critical side effects during that therapy. After residual disease was proven by biopsy, docetaxel, cisplatin and 5-fluorouracil (TPF) therapy was introduced as adjuvant chemotherapy. The patient developed a high fever with a decreased neutrophil count on day 8, and went into a state of shock on day 9. He underwent immediate systemic management, but methicillin-resistant Staphylococcus aureus (MRSA) pneumonia and enteritis were uncontrolled, resulting in death on day 43. The autopsy findings suggested that the main cause of death was acute respiratory distress syndrome (ARDS), but cytomegalovirus (CMV) infection was also noted in multiple organs. . Since it is assumed from literature that the mortality rate in TPF therapy is about 2-4%, it was considered that prior sufficient explanations and informed consent should be required before this therapy.

Download full-text PDF

Source
http://dx.doi.org/10.3950/jibiinkoka.118.763DOI Listing

Publication Analysis

Top Keywords

febrile neutropenia
8
adjuvant chemotherapy
8
tpf therapy
8
case nasopharyngeal
4
nasopharyngeal cancer
4
cancer febrile
4
death
4
neutropenia death
4
death adjuvant
4
adjuvant chemotherapy]
4

Similar Publications

Introduction: While clinical practice guidelines (CPGs) for pediatric oncology infection prophylaxis and management exist, few data describe actual management occurring at pediatric oncology centers.

Methods: An electronic survey querying infection management practices in nontransplant pediatric oncology patients was iteratively created by the Children's Oncology Group (COG) Cancer Control and Supportive Care Infectious Diseases Subcommittee and sent to leaders at all COG institutions, limiting each site to one response to represent their institution.

Results: The response rate was 57% (129/227 institutions).

View Article and Find Full Text PDF

Cathelicidin, but not vitamin D, is associated independently with sepsis in pediatric patients with cancer and febrile neutropenia.

Mol Clin Oncol

February 2025

Clinical Pharmacology Laboratory, Facultad de Estudios Superiores Zaragoza, Universidad Nacional Autónoma de México, Mexico City 09230, Mexico.

Sepsis and septic shock are major complications of febrile neutropenia (FN) in pediatric patients with cancer (PPCs). The aim of the present study was to determine the association of vitamin D (VD) and cathelicidin levels with sepsis and septic shock in PPCs with FN. A prospective cohort of PPCs with FN who had previously received cytotoxic chemotherapy was analyzed.

View Article and Find Full Text PDF

: Empirical antibacterial therapy for febrile neutropenia reduces mortality due to Gram-negative blood stream infections (BSIs). Pediatric guidelines recommend monotherapy with an antipseudomonal beta-lactam or a carbapenem and to add a second anti-Gram-negative agent in selected situations. We evaluated the changes in the proportions of resistance of beta-lactam monotherapies vs.

View Article and Find Full Text PDF

Even though venetoclax in combination with azacitidine (VenAza) is considered a low-intensity regimen, its patients present a high incidence of cytopenia and infections during the first courses, making the initial management a challenging phase. This difficulty in our center led to the establishment of an At-Home (AH) program for ramp-up and follow-up patients during the VenAza combination induction phase focused on therapy administration, patient and caregiver education, and management of adverse events (AEs). A total of 70 patients with newly diagnosed acute myeloid leukemia (ND-AML) or relapsed/refractory AML (R/R AML) were treated with VenAza from March 2019 to May 2022.

View Article and Find Full Text PDF

[Prognostic factors for survival in children with cancer and febrile neutropenia].

Andes Pediatr

October 2024

Escuela de Salud Pública, Facultad de Medicina, Universidad de Chile, Santiago, Chile.

Unlabelled: Cancer remains one of the most important diseases in public health.

Objective: To estimate 5-year survival in pediatric cancer patients affected by FN, according to clinical-demographic variables.

Patients And Method: Survival, prognostic, and analytical study with historical cohort.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!